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Abstract
Purpose Epidermal growth factor receptor inhibitors such
as panitumumab are associated with characteristic skin
toxicities. We summarise data from three panitumumab
clinical trials to investigate the potential impact of skin
toxicity on quality of life (QoL) in patients with metastatic
colorectal cancer (mCRC).
Methods The studies were randomised, open-label trials
comparing standard treatment (first-line FOLFOX4
[n = 456], second-line FOLFIRI [n = 381], or best sup-
portive care [n = 114]) with or without panitumumab in
adults with KRAS/NRAS (RAS) wild-type mCRC. QoL was
assessed using the EuroQoL 5-domain health state index
(HSI) and overall health rating (OHR) measures. Impact of
skin toxicity on changes in QoL scores was estimated using
a linear mixed-effects model. Worst skin toxicity was
defined in separate models as a subgroup variable or as a
measure over time.
Results Regardless of analysis method, there were no
statistically significant differences between the panitu-
mumab and comparator arms in any of the studies in terms
of change in HSI or OHR scores. There were no statisti-
cally significant differences in QoL outcomes between
patients with worst skin toxicity grade\3 and those with
grade C3. In addition, there were no statistically significant
differences between the panitumumab and comparator
arms in subgroups of patients with worst skin toxicity of
grade\3 and C3.
Conclusions Addition of panitumumab to chemotherapy
in RAS wild-type mCRC has no statistically significant
negative effect on overall QoL, despite skin toxicity. Skin
toxicity of worst grade C3 appeared to have similar impact
on QoL as skin toxicity of grade\3.
Keywords Quality of life  Colorectal cancer 
Panitumumab  Epidermal growth factor receptor
inhibitors  Skin toxicity
Introduction
The epidermal growth factor receptor (EGFR) is a receptor
tyrosine kinase that plays a key role in the development and
progression of some tumours, particularly colorectal car-
cinoma [1]. It is therefore an attractive target for anticancer
therapies. Panitumumab is a fully human monoclonal
antibody that targets EGFR [2]. Studies have shown that
panitumumab can significantly improve progression-free
survival (PFS) across several lines of treatment in patients
with metastatic colorectal cancer (mCRC) whose tumours
are wild type (WT) for the RAS oncogene (i.e. no
detectable mutations in both the KRAS and NRAS genes)
[3–6]. In particular, addition of panitumumab to
chemotherapy with leucovorin, 5-fluorouracil, and oxali-
platin (FOLFOX, as either the standard FOLFOX4 or the
more intensive FOLFOX6 regimen) in first-line treatment
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has been shown to improve overall survival (OS) versus
FOLFOX alone [3] and versus FOLFOX plus bevacizumab
[7] in patients with WT RAS or KRAS mCRC. As a result,
panitumumab was licensed for the treatment of patients
with RAS WT mCRC. The licensed indications in Europe
are first-line therapy in combination with FOLFOX or
FOLFIRI (leucovorin, 5-fluorouracil, and irinotecan), as
second-line therapy in combination with FOLFIRI, and as
monotherapy after failure of multiple chemotherapy regi-
mens [8].
Adverse events during cancer treatment can have a
negative effect on quality of life (QoL) [9, 10], and optimal
therapy, therefore, involves a balance between efficacy and
safety [11]. Dermatological toxicities such as papulopus-
tular rash (acneiform eruption), erythema, and skin fissures
are common side effects of targeted cancer agents such as
EGFR inhibitors [12], as EGFR is involved in the normal
development and physiology of the epidermis. It has been
reported that emergence of skin toxicity may be a surrogate
clinical marker for efficacy of EGFR inhibitors in mCRC,
although this remains controversial, with few prospective
studies. Studies have also investigated the link between
QoL and outcomes in colorectal cancer, showing that
baseline QoL is an independent predictor for survival [13].
In patients receiving panitumumab in combination with
FOLFOX, the occurrence of skin toxicity has been corre-
lated with improved survival outcomes in patients with
mCRC [14], but this association is not clear and may be
related to the longer duration of treatment in patients
responding to panitumumab.
As part of three clinical trials of different lines of
treatment with panitumumab in patients with mCRC, QoL
data were collected as pre-specified tertiary endpoints: the
20050203 (‘PRIME’; NCT00364013) study in first-line
treatment of mCRC [15]; the 20050181 (‘181’;
NCT00339183) study in second-line treatment [16]; and
the 20020408 (‘408’; NCT00113763) study in third- or
fourth-line treatment [17]. Given that skin toxicity is a
common side effect of panitumumab, we summarise QoL
data from patients with RAS WT mCRC in those three
studies to investigate a potential relationship between skin
toxicity and QoL in patients receiving panitumumab.
Methods
Study designs and patients
Full details of the study design and inclusion criteria for the
three included studies have been published previously [15,
17, 18]. All three studies were randomised, open-label
phase III trials comparing a standard treatment regimen
(PRIME, first-line FOLFOX4; 181, second-line FOLFIRI;
408, best supportive care [BSC]) with or without panitu-
mumab. Eligible patients in each study were aged
C18 years and had an Eastern Cooperative Oncology
Group performance status of 0-2. In all three studies the
panitumumab dose was 6.0 mg/kg every 2 weeks, and PFS
was a primary endpoint. OS was a primary endpoint in the
181 study and a secondary endpoint in the other two
studies, with other secondary endpoints in all three studies
including objective tumour response and safety. The pre-
sent analyses use data from the subset of patients with RAS
WT mCRC from these three studies [3–5].
The protocols of all three studies were approved by the
ethics committees at participating sites and adhered to all
ethical guidelines, and all patients signed informed consent
before any study-related procedures were performed.
Skin toxicity
Adverse events were collected throughout treatment and
safety follow-up in all three studies and graded according to
National Cancer Institute’s Common Toxicity Criteria (ver-
sion 3.0) [19], with the exception of panitumumab-related
skin toxicities, which were graded using a modified version
of the CTC version 3.0. Severity of adverse events was rated
on a five-point scale: 1 = mild; 2 = moderate; 3 = severe;
4 = life threatening or disabling; and 5 = death.
QoL endpoints and analyses
QoL was assessed as a pre-specified tertiary endpoint
during each study, using the EuroQoL 5-domain (EQ-5D)
health state index (HSI) and overall health rating (OHR)
measures. HSI scores range from -0.594 to 1.0 (higher
scores represent better health, with 1.0 equivalent to perfect
health), while OHR comprises a 0-100 visual analogue
scale, with 0 representing ‘Worst imaginable health state’
and 100 representing ‘Best imaginable health state’. QoL
was assessed B7 days before randomisation and every
4 weeks until disease progression, with a final assessment at
a safety follow-up visit. For all analyses, minimally impor-
tant differences (MIDs) were defined as 0.08 for HSI and 7
for OHR [20]. A descriptive analysis of the distribution of
worst skin toxicity grades in patients with a decrease in HSI
or OHR exceeding the MID was also performed.
Primary and secondary QoL analyses were conducted on
the RAS WT patient-reported outcome (PRO) patient
cohort, defined as the subsets of RAS WT patients in each
intent-to-treat analysis set who received at least one dose of
study medication, and had a baseline QoL assessment and
at least one post-baseline QoL assessment. This is an
exploratory analysis without type-I error rate control, and
all p values are descriptive.
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Primary analysis
The impact of worst skin toxicity grade on the changes
from baseline to discontinuation of treatment in QoL scores
was estimated using a linear mixed-effects model for
repeated measures [21]. The mixed-effects model was used
for all regression analyses and adjusted for treatment, visit,
worst skin toxicity grade, and baseline HSI scores (termed
as fixed effects), with intercept and visit as random effects.
Worst skin toxicity grade was defined in two different ways
in the linear mixed-effect models. In definition 1, between-
treatment differences were assessed adjusting for fixed
effects terms and significant covariate-by-covariate inter-
actions at the 5 % level. Differences by worst skin toxicity
level (grade\3 vs. C3) were evaluated adjusting for fixed
effects terms and significant covariate-by-covariate inter-
actions at the 5 % level. Between-treatment differences for
each worst skin toxicity level (grade \3 and C3) were
assessed using a full model with interactions included. In
definition 2, worst skin toxicity was included as a measure
over time (i.e. worst skin toxicity grade was assigned to
each QoL assessment visit). Covariate-by-covariate inter-
actions were assessed and retained in the model if statis-
tically significant at the 5 % level, and between-treatment
differences were assessed adjusting for fixed effect terms
and significant interactions.
Secondary analyses
In addition to the primary analysis, the distribution of worst
skin toxicity grades by treatment arm for all grades was
calculated in the subset of patients who had clinically
meaningful decreases from baseline in QoL scores. As a
sensitivity analysis, the mixed-effect model was repeated
without skin toxicity as a covariate, and between-treatment
differences were assessed adjusting for treatment, visit,




The RAS WT PRO sets for PRIME included 232 patients
who received panitumumab ? FOLFOX4 and 224 who
received FOLFOX4 alone; for the 181 study included 187
patients who received panitumumab ? FOLFIRI and 194
who received FOLFIRI alone; and for the 408 study
included 66 patients who received panitumumab ? BSC
and 48 who received BSC alone. Baseline demographics,
disease characteristics, and QoL scores for patients in the
three studies are shown in Table 1. Demographics and
disease characteristics were generally similar across studies
and between treatment groups, although median QoL
scores were lower in the 408 study than in PRIME or 181.
Overall rates of compliance with QoL assessment (ex-
pressed as evaluable vs. expected assessments) were 57 %
for both QoL assessments in the PRIME study, 64 % for
HSI and 63 % for OHR in 181 study, and 72 % for both
QoL assessments in the 408 study.
Quality of life
Using skin toxicity definition 1, there were no statistically
significant differences between the panitumumab and
comparator arms in any of the three studies in terms of HSI
or OHR scores from baseline to discontinuation (Table 2a).
The between-group difference for HSI in the 408 study,
however, was larger than the MID of 0.08, favouring BSC
alone. Results were similar when using definition 2
(Table 2b) and when skin toxicity was removed from the
mixed-effect model (Online Resource 1).
Skin toxicity
The most common skin toxicities in the three studies are
shown in Table 3a, with the distribution of worst skin
toxicity grades by treatment in each study shown in Fig. 1.
In the PRIME study, 5 % of patients overall discontinued
treatment because of skin toxicities (panitumumab ?
FOLFOX, 8 %; FOLFOX, 1 %). In the 181 study, 4 % of
patients overall discontinued treatment because of skin
toxicities (panitumumab ? FOLFIRI, 7 %; FOLFIRI,
0.5 %). The median number of treatment cycles received
before discontinuation because of skin toxicity in the
PRIME study was seven in the panitumumab ? FOLFOX
arm and 12 in the FOLFOX arm. The median number of
treatment cycles received before discontinuation because
of skin toxicity in the 181 study was five in the panitu-
mumab ? FOLFIRI arm and one in the FOLFIRI arm. The
most common skin toxicities leading to discontinuation in
the PRIME and 181 studies are shown in Table 3b. No
patient discontinued because of skin toxicity in the 408
study.
Analysis of quality of life by skin toxicity
Using skin toxicity definition 1, there were no statistically
or clinically significant differences in QoL outcomes
between patients with worst skin toxicity of grade\3 and
those with grade C3 in any of the three studies (Table 4).
In addition, there were no statistically significant differ-
ences between the panitumumab and comparator arms in
subgroups of patients with worst skin toxicity grade \3
(Table 5), although the between-group difference in HSI in
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the 408 study (-0.112) was greater than the MID in favour
of BSC. In the PRIME and 181 studies, there were no
statistically significant differences between the panitu-
mumab and comparator arms in patients with worst skin
toxicity grade of C3, although the difference in OHR in the
181 study (-8.21) was greater than the MID in favour of
FOLFIRI alone (Table 5). In the 408 study, no patient in
the BSC alone arm experienced grade C3 skin toxicity, so
no comparison was possible.
The distributions of worst skin toxicity grades in
patients with a decrease in QoL greater than the MIDs for
HSI or OHR are shown in Fig. 2.
Discussion
While the addition of panitumumab to chemotherapy or
BSC is associated with skin toxicity—as demonstrated by
the distribution of worst grade skin toxicity in each treat-
ment arm—results from these analyses show no statistically
significant negative impact of panitumumab treatment on
overall QoL. In addition, there was no apparent difference in
distribution of worst skin toxicity grade in patients with a
decrease in QoL compared with the overall population.
In first- and second-line therapy, addition of panitu-
mumab to chemotherapy had no clinically significant
impact on overall QoL. Indeed, a recent quality-adjusted
time without symptoms of disease or toxicity (Q-TWiST)
analysis from the PRIME study showed that panitumumab
plus FOLFOX4 significantly improved quality-adjusted
survival time compared with FOLFOX4 alone (20.5 vs.
18.2 months, respectively; p = 0.025) [22]. In later lines of
therapy (408 study), the difference in HSI between the
panitumumab plus BSC and BSC alone arms (-0.111 and
-0.223 for skin toxicity definitions 1 and 2, respectively)
was greater than the MID (0.08), although not statistically
significant. This is in contrast to an earlier analysis of QoL
in the KRAS WT population of the 408 study, which
showed a small, but clinically significant benefit for pani-
tumumab plus BSC over BSC alone on the EQ-5D HSI
[23]. Furthermore, a previous Q-TWiST analysis of PFS
and OS in the 408 study showed that panitumumab plus
BSC significantly improved quality-adjusted survival
compared with BSC alone in patients with KRAS WT
mCRC [24]. Importantly, the small patient cohort in the
408 study should be taken into account when interpreting
the results reported here. In addition, while a clinically
meaningful difference between the panitumumab plus
FOLFIRI and FOLFIRI alone arms was observed for
patients with worst skin toxicity grade C3 in the 181 study,
this is probably the result of the small number of patients in
the FOLFIRI arm with skin toxicity of grade C3.
While skin toxicity might be expected to have a negative
impact on QoL, there were no statistically or clinically sig-
nificant differences in QoL between patients with worst skin
toxicity grade\3 and those with grade C3 in these explora-
tory analyses. Furthermore, few patients discontinued as a
result of skin toxicity in any of the three studies. While skin
Fig. 1 Distribution of worst
skin toxicity by treatment arm in
each study
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toxicity had no impact on global QoL, it is important to note
that it remains a clinically relevant adverse event that requires
proactive management [12].
Overall, our results are consistent with previous studies
of first- and second-line EGFR inhibitor therapy in mCRC.
For example, similar results were seen in an earlier analysis
of QoL data from patients with KRAS WT mCRC in the
PRIME study [25], as well as in a recent analysis of EQ-5D
subscales [26]. In studies of first-line FOLFIRI combined
with panitumumab or cetuximab, another EGFR inhibitor
licensed for treatment of mCRC, no negative effect on QoL
or social functioning has been observed during treatment
[27, 28]. Similarly, a study of panitumumab added to
second-line FOLFIRI showed that panitumumab improved
PFS without compromising QoL [24]. A study of the
psychological effects associated with cetuximab treatment
in 80 consecutive patients treated at a single centre (any
treatment line) showed that psychological distress was
present in 41 % of patients [29]. Notably, there was a link
between distress and overall QoL, but distress was not
specifically linked with rash, which did not affect psy-
chological status or social life. In another cetuximab study,
patients with mCRC experienced psychological distress
initially, as they processed their cancer diagnosis and
dermatological side effects at the same time [30]. Later in
the course of treatment, however, skin reactions no longer
had a significant influence on health-related QoL, possibly
because patients link the development of skin toxicities
with the action of the drug and, by association, the prob-
ability of an effective treatment response.
The QoL scales used in these studies, including the EQ-
5D, are measures of global QoL and are not specific for
skin toxicity. The negative impact of rash-related events
may therefore have been balanced by treatment-related
effects, particularly in patients receiving earlier lines of
therapy. For example, as noted above, patients with
advanced cancer may consider skin rash to be part of their
overall condition or to be a marker of efficacy [29, 30]. It is
also possible that the beneficial effects of treatment—re-
lating, for example, to symptom relief [26]—may outweigh
skin-related side effects [10]. It should also be noted that
rash is an expected adverse event with EGFR inhibitors,
which means that physicians are able to discuss it with their
patients in advance and initiate prophylactic therapy and
proactive management of symptoms. The lack of a differ-
ence in QoL associated with different grades of skin toxi-
city suggests, however, that QoL tools specific for skin-
related events are required to assess the direct effect of skin
toxicity on QoL for patients receiving EGFR inhibitors.
In conclusion, the addition of panitumumab to
chemotherapy in first- or second-line RAS WT mCRC has
no negative effect on overall QoL, despite the occurrence



































































































































































































































































































































































































































































































































































































































2652 Qual Life Res (2016) 25:2645–2656
123
panitumumab monotherapy to BSC was associated with no
statistically significant negative effect on QoL, although
some between-treatment differences were greater than the
MID. In all three studies, skin toxicity of a worst grade of
C3 appeared to have similar impact on QoL outcomes as
skin toxicity of grade \3. While skin toxicity had no
impact on overall QoL, it is a clinically relevant adverse
event that requires proactive management. It should also be
noted that the QoL scale used in these studies was a generic
questionnaire, and differences may have been observed if a
skin-specific QoL instrument had been used. Further
research is needed, using QoL tools specific for skin-
Table 5 Mixed-effect linear model of change from baseline to discontinuation of treatment in EuroQoL 5-domain health state index and overall
health rating scores by treatment group and worst skin toxicity grade in the (a) PRIME, (b) 181, and (c) 408 studies (skin toxicity definition 1)
Worst skin toxicity grade
\3 C3
Panitumumab ? FOLFOX4 FOLFOX4 Panitumumab ? FOLFOX4 FOLFOX4
(a)
Health state index n = 136 n = 215 n = 88 n = 6
Adjusted LS mean -0.003 0.011 -0.004 0.009
95 % confidence intervals -0.033, 0.027 -0.014, 0.036 -0.040, 0.032 -0.116, 0.134
Difference -0.015 (-0.053, 0.024) -0.013 (-0.140, 0.114)
Overall health rating n = 136 n = 212 n = 86 n = 6
Adjusted LS mean -0.30 0.66 -1.56 2.10
95 % confidence intervals -2.83, 2.23 -1.46, 2.78 -4.66, 1.54 -8.36, 12.57
Difference -0.96 (-4.23, 2.32) -3.66 (-14.30, 6.98)
Worst skin toxicity grade
\3 C3
Panitumumab ? FOLFIRI FOLFIRI Panitumumab ? FOLFIRI FOLFIRI
(b)
Health state index n = 111 n = 188 n = 75 n = 6
Adjusted LS mean -0.019 -0.022 -0.038 0.032
95 % confidence intervals -0.051, 0.014 -0.047, 0.004 -0.074, -0.001 -0.100, 0.164
Difference 0.003 (-0.038, 0.044) -0.070 (-0.206, 0.066)
Overall health rating n = 110 n = 184 n = 72 n = 6
Adjusted LS mean -2.10 -0.61 -1.39 6.82
95 % confidence intervals -4.47, 0.26 -2.53, 1.32 -4.15, 1.38 -2.04, 15.68
Difference -1.50 (-4.53, 1.53) -8.21 (-17.26, 0.85)
Worst skin toxicity grade
\3 C3
Panitumumab ? BSC BSC Panitumumab ? BSC BSC
(c)
Health state index n = 50 n = 45 n = 11 n = 0
Adjusted LS mean -0.027 0.084 0.026 -
95 % confidence intervals -0.096, 0.042 -0.122, 0.291 -0.146, 0.199 -
Difference -0.112 (-0.329, 0.106) -
Overall health rating n = 48 n = 45 n = 11 n = 0
Adjusted LS mean -2.47 -3.08 3.54 -
95 % confidence intervals -5.72, 0.77 -14.57, 8.41 -3.51, 10.59 -
Difference 0.60 (-11.36, 12.57) -
BSC best supportive care, FOLFIRI leucovorin, 5-fluorouracil, and irinotecan, FOLFOX leucovorin, 5-fluorouracil, and oxaliplatin, LS least
squares
Qual Life Res (2016) 25:2645–2656 2653
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related events, to assess the direct effect of skin toxicity on
QoL for patients receiving EGFR inhibitors.
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